trending Market Intelligence /marketintelligence/en/news-insights/trending/eQBQzzwwJMVcnr6qxMAuiw2 content esgSubNav
In This List

Horizon Pharma under US DOJ investigation over PBM-related payments

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Horizon Pharma under US DOJ investigation over PBM-related payments

Horizon Pharma PLC said it received a civil investigative demand from the U.S. Department of Justice for alleged kickbacks involving certain payments made to pharmacy benefit managers.

According to the Irish company, the U.S. justice department is requesting certain documents and information regarding the payments to pharmacy benefit managers, which were flagged for potential violation of the Anti-Kickback Statute.

The company made these payments to PBMs, pricing and its patient assistance program to cover rheumatoid arthritis and osteoarthritis drugs Duexis, Vimovo and Pennsaid 2%.

Horizon Pharma announced its intention to cooperate with the investigation. The healthcare company also noted its belief that its payments and programs are in compliance with the federal law.

Dublin-based Horizon Pharma develops and commercializes medicines that address unmet treatment needs for rare and rheumatic diseases.